← Back to Screener
PDS Biotechnology Corporation Common Stock (PDSB)
Price$1.02
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)24.37%
Price vs S&P 500 (4W)-18.39%
VGM Score56.99
Market Capitalization$56.93M
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)4.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)24.34%
EPS (TTM)$-0.68
10-Day Avg Trading Volume1.22M
EPS Excl Extra (TTM)$-0.68
EPS (Annual)$-0.74
ROI (Annual)-131.78%
Cash / Share (Quarterly)$0.39
ROA (Last FY)-113.12%
EBITD / Share (TTM)$-0.58
ROE (5Y Avg)-170.94%
Cash Flow / Share (Annual)$-0.51
P/B Ratio14.63x
P/B Ratio (Quarterly)8.67x
Net Income / Employee (Annual)$-1,642,600
Net Interest Coverage (TTM)-10.83x
ROA (TTM)-102.37%
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)2.98x
Quick Ratio (Quarterly)2.13x
3-Month Avg Trading Volume0.85M
52-Week Price Return-34.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
52-Week High$1.92
EPS Excl Extra (Annual)$-0.74
Tangible BV CAGR (5Y)-6.74%
26-Week Price Return32.30%
Quick Ratio (Annual)2.82x
13-Week Price Return54.45%
Total Debt / Equity (Annual)1.83x
Current Ratio (Quarterly)2.26x
Enterprise Value$51.13M
Book Value / Share Growth (5Y)-32.63%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.49
3-Month Return Std Dev154.34%
Net Income / Employee (TTM)$-1,588,400
ROE (Last FY)-372.85%
Net Interest Coverage (Annual)-6.59x
EPS Basic Excl Extra (Annual)$-0.74
Total Debt / Equity (Quarterly)4.07x
EPS Incl Extra (TTM)$-0.68
ROI (TTM)-123.71%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.46
Price vs S&P 500 (52W)-58.98%
Year-to-Date Return32.50%
5-Day Price Return-10.53%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-69.32%
Month-to-Date Return-5.56%
Cash Flow / Share (TTM)$-1.69
EBITD / Share (Annual)$-0.70
LT Debt / Equity (Annual)1.27x
ROI (5Y Avg)-79.47%
LT Debt / Equity (Quarterly)2.72x
EPS Basic Excl Extra (TTM)$-0.68
P/TBV (Quarterly)1.24x
P/B Ratio (Annual)4.55x
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)46.20%
Beta1.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-346.03%
52-Week Low$0.51
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.15
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PDSBPDS Biotechnology Corporation Common Stock | — | — | C | $1.02 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments across multiple indications including head and neck, breast, prostate, cervical, and anal cancers. The company's proprietary Versamune platform harnesses the immune system to specifically target cancer cells. Its pipeline is built on this differentiated technology platform.